MicroRNAs in Vascular Eye Diseases

Abstract

Since the discovery of the first microRNA (miRNA) decades ago, studies of miRNA biology have expanded in many biomedical research fields, including eye research. The critical roles of miRNAs in normal development and diseases have made miRNAs useful biomarkers or molecular targets for potential therapeutics. In the eye, ocular neovascularization (NV) is a leading cause of blindness in multiple vascular eye diseases. Current anti-angiogenic therapies, such as anti-vascular endothelial growth factor (VEGF) treatment, have their limitations, indicating the need for investigating new targets. Recent studies established the roles of various miRNAs in the regulation of pathological ocular NV, suggesting miRNAs as both biomarkers and therapeutic targets in vascular eye diseases. This review summarizes the biogenesis of miRNAs, and their functions in the normal development and diseases of the eye, with a focus on clinical and experimental retinopathies in both human and animal models. Discovery of novel targets involving miRNAs in vascular eye diseases will provide insights for developing new treatments to counter ocular NV.

1. Introduction

The Human Genome Project from 1990 to 2003 provided, for the first time, complete comprehensive information on human genome sequences with their entire complexity and thereby started the post-genomic era [1,2]. This era is marked in part by extensive studies on non-coding RNAs (ncRNAs), which do not encode for proteins yet still account for more than 98.5% of human genome transcripts [1,2]. While the housekeeping ncRNAs, such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), have already been shown to exhibit relatively clear functions, the regulatory ncRNAs including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), once considered “junk” RNAs, have more recently been found to play important roles in a wide variety of physiological and pathological processes, and hence have become attractive targets in deciphering and treating human diseases. Among these regulatory ncRNAs, miRNAs are arguably one of the most widely studied ncRNAs in biomedical research.

First identified in 1993 [3], miRNAs are a class of naturally occurring small ncRNAs ranging in size from 19 to 25 nucleotides, and their major function is in regulating gene expression at the post-transcriptional level [4]. Since the initial discovery, thousands of miRNAs have been found in various species and the number of miRNAs continues to increase. In the human genome, expression of up to 60% of protein-coding genes may be regulated by miRNAs, indicating their pervasive role in multiple biological processes such as proliferation, apoptosis, differentiation, and development [5,6,7,8]. Importantly, dysregulation of miRNA is found to be involved in many diseases, such as various cancers, cardiovascular diseases, and neurodegenerative disorders. Genetic variation of miRNAs is also linked with several inherited diseases including hearing loss and growth defects. Given their biological importance, miRNAs are currently recognized as novel disease biomarkers and potential therapeutic targets for developing new interventions [8,9,10].

2. miRNA Biogenesis and Function

The biogenesis of miRNAs starts in the nucleus, where miRNA genes are transcribed primarily by RNA polymerase II (Pol II) into long primary miRNA transcripts (pri-miRNAs), which contain one or more hairpin structures and can be more than 1000 nucleotides long [11]. Pri-miRNAs are then processed by the RNaseIII endonuclease, Drosha, along with its co-factor protein DGCR8 (DiGeorge syndrome critical region 8) into the resulting much shorter precursor miRNAs (pre-miRNAs), usually about 70 nucleotides long, which are then transported to the cytoplasm via exportin-5 [12,13,14,15]. In the cytoplasm, the pre-miRNAs are subsequently cleaved by another RNaseIII endonuclease, Dicer, with assistance from TAR RNA binding protein (TRBP), which together remove the terminal loop, and generate a miRNA duplex [16]. After double-strand RNA unwinding, the mature miRNA strand is selected by the argonaute (AGO) family protein, and assembled into an RNA-induced silencing complex (RISC). This complex may then bind downstream targets to act through translational repression or mRNA cleavage [17,18] (Figure 1). miRNAs function by base-paring to the complementary sequence in the 3′ untranslated region (3′UTR) of target mRNAs to either induce mRNA degradation, promote deadenylation, or reduce translational efficacy [4,19]. Based on these features, miRNAs are considered key mediators of post-transcriptional regulation through fine-tuning gene expression.

3. miRNA as Clinical Biomarkers

Over the past two decades, numerous studies recognize the clinical value of miRNAs in the diagnosis of virtually all major diseases, including cancers, cardiovascular diseases, and neurodegenerative diseases. The deregulation of miRNAs in cancer was first reported in chronic lymphocytic leukemia in 2002 [20]. Since then, extensive evidence points to largely altered expression levels of miRNAs in various types of cancers; and suggests the immense diagnostic potential of miRNA alteration, specifically circulating miRNAs, as biomarkers [21]. The diagnostic value of many circulating miRNAs has been reported for both chronic and acute leukemia (e.g., miR-10, miR-29, miR-31, miR-34, miR-130b, miR-146a, miR-148, miR-150, miR-155, miR-181b-5p, miR-192, miR-203, miR-210, miR-212, miR-328, miR-335, miR-342, miR-375) [22,23,24,25,26,27], breast cancer (e.g., miR-9, miR-10b, miR-21, miR-155, miR-181a-5p and miR-192) [28,29,30,31,32], lung cancer (e.g., miR-7, miR-25, miR-193a-3p, miR-214, and miR-483-5p) [33,34,35,36,37], and other human cancers [38], to name just a few. Besides cancer, circulating miRNAs are also implicated in the diagnosis of cardiovascular diseases and neurodegenerative diseases. For instance, miR-1, miR-133a, miR-133b, miR-145, miR-208a, miR-208b, and miR-499, may have diagnostic potential for coronary heart disease [39]; whereas four decreased serum miRNAs, namely miR-141, miR-146b-5p, miR-193a-3p, and miR-214, are suggested as biomarkers to detect early stages of Parkinson’s disease [40]. In addition, mutations in miRNAs are also associated with inherited diseases, including miR-96 in progressive hearing loss [41], miR-184 in familial keratoconus with cataract [42], and the miR-17~92 cluster in skeletal and growth defects [43]. Together these findings strongly suggest the useful value of miRNAs as clinical biomarkers and diagnostic tools to identify diseases in multiple organs.

4. miRNA in the Eye

Just like elsewhere in the body, the function of miRNAs has shown increasing relevance in the eye. In the back of the eye, the retina is comprised of a thin layer of neuronal tissue of diverse cell types and is equipped with a highly specialized light-sensing capacity (Figure 2). Fine-tuning gene expression for cell differentiation and function is crucial for vertebrate retinal development and proper vision. Given its major impact on gene regulation, miRNA serves a vital role in the retina throughout development and in eye diseases [44,45,46]. Previous animal studies examining the effects of Dicer-deficiency in retinal development identified the differential expression patterns of many miRNAs in vertebrate neural retinas [47,48,49,50,51,52,53,54,55,56], and developed the ability to categorize retinal cells through specific miRNA signatures (Figure 2).

In the developing eye of several species including mammals, amphibians, and fish, miRNA expression patterns were analyzed using a variety of different approaches [48,52,54,58,59,60,61]. Although the expression profiles of miRNAs vary across species and also differ based on the methods of analysis, some specific miRNAs demonstrate their similar patterns and common roles in retinal development, and in both structural and functional maintenance [62,63,64]. For example, miR-204, one of the most abundant miRNAs in the retina, regulates multiple aspects of eye development [60,61]. Ablation of miR-204 results in abnormal lens formation, altered dorsoventral patterning of the retina, dedifferentiation of the retinal pigment epithelium (RPE), microphthalmia, and coloboma [62,63]. It is strongly expressed in the ganglion cell layer (GCL), the inner nuclear layer (INL), and the RPE [61,65]. In addition, miR-211, another member of the miR-204/211 subfamily, is highly similar to miR-204 in its sequence, target capability, and expression pattern. Loss of miR-211 in mice results in progressive cone dystrophy which is accompanied by the degeneration of cone cells and reduced visual responses detected from electroretinogram (ERG) [66].

Some miRNAs important for brain neural development also play crucial roles in the retina, as a part of the central nervous system (CNS). miR-124, enriched in the vertebrate CNS, is one the most well studied miRNAs in the developing retina [51,52,54,61,64,67,68,69,70,71,72,73,74]. miR-124 targets Lhx2, a transcriptional factor essential for CNS development, and hence it is important in the maturation and survival of both dentate gyrus neurons and retinal cone photoreceptors. miR-124 is expressed in all retinal neuronal cell layers with the most prominent expression in photoreceptors [46,64]. Abolishing miR-124a in mice leads to mislocalization and apoptosis of cone photoreceptors, altered expression of cone-specific genes and reduced photopic ERG [64]. In addition to photoreceptors, miR-124 is expressed in other retinal neuronal cell layers and contributes to their functions. For instance, in donor eyes from patients with age-related macular degeneration (AMD) and in mouse models of retinal degeneration, miR-124 exhibits a time-dependent altered expression pattern from the outer nuclear layer (ONL) neurons to the Müller glia in the INL, followed by its eventual depletion at a later stage [75]. miR-132, another critical miRNA in brain neural synaptic growth [76], is also important for retinal neurons. As a member of the miR-132/212 cluster, miR-132 shapes brain synapse formation and influences visual cortex plasticity [77]. In the eye, miR-132 promotes axon formation of retinal ganglion cells (RGCs), and is expressed in GCL and INL under the control of brain-derived neurotrophic factor (BDNF) [78].

Given the crucial role of the aforementioned miRNAs in ocular and retinal development and their functional conservation across species, it is plausible that altered expression of miRNAs may lead to ocular disorders, including those vascular eye diseases that are characterized by primary abnormalities in retinal blood vessels which control metabolic availability of oxygen and nutrients to impact retinal neurons.

5. miRNA and Angiogenesis

To understand the roles of miRNAs in vascular eye diseases, here we first summarize the function of miRNAs in angiogenesis. Angiogenesis is the process of new vessels sprouting from existing vessels, which is orchestrated by various angiogenic stimulators and inhibitors, including miRNAs. Angiogenesis plays crucial roles in both physiological development and homeostasis, as the vascular system delivers nutrients to organs and tissues and removes catabolic products [79,80]. Dysregulation of vascular growth is associated with many cardiovascular diseases, cancers, neurodegenerative disorders, and vascular eye diseases [81,82]. Abnormal angiogenesis disrupts the delivery of oxygen and nutrients, which can lead to an unbalanced metabolic status, and result in structural instability and functional loss of affected tissues. Many eye diseases with vascular components are marked by pathologic ocular neovascularization (NV), characterized by a leaky, fragile, and tuft-liked appearance, which may cause retinal hemorrhage and lead to retinal damage and/or tractional retinal detachment, and ultimately result in vision loss in the most severe cases [83].

The importance of miRNAs in angiogenesis and endothelial function was first established by analysis of Dicer- and Drosha-deficient mice with defective miRNA biosynthesis [84,85,86,87]. Mouse embryos with a Dicer hypomorphic mutation have defective angiogenesis accompanied by reduced miRNA production and dysregulation of angiogenic genes [84,85]. In addition, the knockdown of Dicer and Drosha in human endothelial cells (ECs) suppresses angiogenic functions, including sprouting, tubular formation and migration [86]. Moreover, mice with conditional EC-specific loss of Dicer exhibit reduced vascular endothelial growth factor (VEGF)-driven angiogenesis postnatally, along with an altered set of angiogenic regulating miRNAs [87].

Several miRNAs are highly expressed in vascular endothelium, including miR-126, miR-210, miR-221/222, the miR-17-92 cluster, and the miR-23-27-24 cluster, as revealed by miRNA profiling in human ECs [88,89,90,91,92,93]. These miRNAs are also called “angiomiRs” for their angiogenesis-related targeting genes [89]. For example, miR-126 promotes angiogenesis and enhances VEGF signaling in ECs, as it suppresses sprouty-related protein-1 (Spred1), a negative factor of Ras-MAP kinase pathway involved in VEGF signaling [90,91,92]. miR-126 null mouse embryos have vascular abnormalities and a high mortality rate most likely due to SPRED1 induction, and subsequent diminished MAP kinase signaling in response to VEGF [91]. miR-210, another angiomiR and hypoxia-induced endothelial miRNA, regulates angiogenesis and cell survival in response to hypoxia [93,94]. Overexpression of miR-210 increases VEGF-driven EC migration and tube formation by targeting Ephrin-A3, an angiogenic receptor tyrosine kinase [93,95,96]. The miR-23-27-24 cluster is highly enriched in ECs and vascularized tissues [97,98]. Whereas miR-23 and miR-27 act as enhancers of angiogenesis in vascular development and pathological angiogenesis [97,99,100], miR-24 inhibits cardiac angiogenesis [98]. Similarly, miR-221/222 is identified as an anti-angiogenic miRNA by targeting c-Kit, the tyrosine kinase receptor of pro-angiogenic stem cell factor (SCF). Overexpressing miR-221/222 in HUVECs suppresses c-Kit and thereby inhibits SCF-mediated angiogenic abilities, such as tubular formation and migration [88]. In addition, the miR-17-92 cluster is a well-characterized polycistronic miRNA that functions as another intrinsic anti-angiogenic regulator in human ECs [101]. Individual miRNAs of this cluster have the ability to cooperate or work independently to modulate multiple signaling pathways, such as the VEGF, Wnt signaling, and PTEN pathways to impact angiogenesis [101,102,103,104]. Together these findings suggest that miRNAs play critical functions in developmental and pathological angiogenesis and are additionally implicated in vascular eye diseases.

6. miRNAs Dysregulation in Neovascular Eye Diseases

Increasing evidence indicates that miRNAs and their biogenesis machinery may be altered and dysregulated in neovascular eye diseases, such as diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP), suggesting the potential of using miRNAs as biomarkers and targeting them for potential therapeutics. In this section, we discuss some prominent examples of clinical studies on miRNAs dysregulation in vascular eye diseases, focusing on miRNAs as potential biomarkers (Table 1).

6.1. miRNAs in DR

DR is one of the most common microvascular complications of diabetes mellitus (DM), which is now recognized as a global epidemic. In the Western world, DR is a leading cause of vision impairment, particularly among individuals of working-age, and poses a significant economic and life quality burden on patients and society [132,133,134]. To find ways to alleviate this burden, it is important to first understand the biochemical basis underlying DR pathogenesis. Hyperglycemia induces alteration in cellular metabolism and causes oxidative injury. Prolonged exposure to hyperglycemia and metabolic changes leads to microvasculature damage in the retinas of diabetic patients. Progressive retinal ischemia eventually stimulates the expression of hypoxia-induced growth factors, such as VEGF, that promote retinal NV [135]. Retinal NV can then cause vitreous hemorrhage or tractional retinal detachment to result in severe vision loss [135,136]. Other major events involved in DR pathogenesis are the breakdown of the blood-retinal barrier and the consequent vascular leakage and thickening of the retina [137]. DR develops in approximately 50% patients with Type 1 diabetes mellitus (T1DM) and over 40% of patients with Type 2 diabetes mellitus (T2DM) by the first decade of incidence [138].

In addition to diagnosing DR through histological examination of the fundus vasculature, circulating miRNAs were found to play critical roles in DR development, suggesting that miRNAs could also serve as new biomarkers in detecting or predicting the progress of retinopathy and furthermore, the overall progress of DM [139,140,141]. Analysis of circulating miRNAs from serum or plasma samples of DM patients both with and without DR showed altered expression levels of many miRNAs throughout different patient populations (e.g., ages, type of DM, years after onset, etc.,) [142]. Among them, miR-27b and miR-320a are the two miRNAs mostly associated with the risks of DR in T1DM [117]. miR-221, an anti-angiogenic miRNA, is significantly altered in DM and is involved in the DM physiopathology and macrovascular complications associated with T2DM [113,114,115,116]. In addition, other circulating miRNAs including miR-126 [105,106,107], miR-150 [109], miR-155 [110], and miR-200b [111] are also dysregulated in DR patients, as well as in pre-clinical animal models of DR [143,144,145,146,147,148,149,150,151,152]. These findings indicate the complex regulation of miRNAs in DR and the potential of miRNAs as biomarkers and/or therapeutic targets for treating DR.

6.2. miRNAs in Neovascular Age-Related Macular Degeneration (wet AMD)

AMD is a leading cause of irreversible loss of central vision in the elderly. Approximately 10–18% of individuals between 65 and 75 will lose some central vision as a result of AMD, while this number increases to 30% for those aged 75 or older [153]. There are two major clinical types of AMD: Atrophic (dry form) AMD with photoreceptor and RPE atrophy; and neovascular (wet from) AMD which is characterized by pathologic subretinal vessels originating from the choroid, i.e., choroidal neovascularization (CNV), the hallmark of wet AMD. Although only 10–20% of AMD patients develop wet AMD, this form of the disease accounts for approximately 80% of severe visual loss in AMD cases [154]. Central vision loss occurs when pathological choroidal neovessels protrude into the subretinal space and subsequently leak blood and cause exudates and hemorrhagic detachment of the retina, thereby resulting in irreversible photoreceptor damage [155].

As a complex, multifactorial, and progressive disease, AMD is linked with both genetic (including complement) and environmental risk factors [155]. Certain miRNAs associated with the complement factor H (CFH)-mediated inflammatory degeneration and neovascularization are dysregulated in the circulating blood or ocular tissues isolated from AMD patients [118,121,156,157]. Two studies identified differential sets of miRNAs altered in plasma collected from wet AMD patients compared to healthy subjects [118,156]. In one study, 16 miRNAs were found to be dysregulated out of 384 miRNAs screened in wet AMD patient plasma samples using quantitative real-time PCR-based methods, with 10 of the 384 miRNAs being exclusively expressed in the wet AMD patient group [118]. Another similar study using next-generation sequencing identified that 3 out of 203 circulating miRNAs were significantly altered in plasma from wet AMD patients vs. non-AMD controls [156]. Moreover, miRNA microarray screening found 23 out of 337 miRNAs were upregulated in the serum from both dry and wet AMD patients vs. non-AMD cohorts. Among them, only 3 miRNAs were expressed at significantly higher levels in the serum of patients with wet AMD [119]. The difference in miRNA profiles from these studies may reflect the variation in their miRNA screening methodology, the nature of samples (plasma vs. serum), the diverse patient population and the different inclusion criteria.

Some miRNAs are altered in both AMD patients and pre-clinical models of AMD, including Let-7, miR-126, and miR-21, all of which are implicated in angiogenic pathways [118,119,120,121]. The Let-7 family, upregulated in AMD patients [118,119], is pro-angiogenic and acts through the inhibition of anti-angiogenic factors tissue inhibitor of metalloproteinase-1 (TIMP-1) and thrombospondin-1 (TSP-1) [84,86,120]. miR-126 and miR-21, both angiomiRs [89,90,91,92,126], are downregulated in the blood samples of AMD patients [118,121], suggesting the dysregulation of angiogenic effects in these patients. Additionally, in experimental models of CNV, miR-126 regulates CNV lesion size [122,123]. These studies revealed the emerging role of miRNAs in AMD and the possibility of targeting miRNAs for suppressing CNV in neovascular AMD.

6.3. miRNAs in Retinopathy of Prematurity (ROP)

ROP is an ocular disease associated with abnormal retinal vascular development that occurs in premature infants and contributes to 6–18% of blindness in children in the developed countries [158,159,160]. ROP is a two-phase disease, beginning with incomplete retinal vessel growth after premature birth, which results in a peripheral avascular zone. As the infant matures, increasing metabolic activities of the peripheral avascular retina cause tissue ischemia and hypoxia. This stimulates a second phase of hypoxia-driven pathological vessel proliferation. In severe cases, pathologic neovessels in the second phase can cause tractional retinal detachment, ultimately leading to blindness [161,162,163]. Current ablation treatments may substantially reduce the incidence of blindness by 25% and improve long-term outcomes in infants with severe ROP. However, these treatments do not address the underlying causes of ROP or other comorbidities, including the failure of normal neuronal and vascular development [163,164,165]. Whether miRNA dysregulation contributes to ROP development has been a subject of recent studies assessing the diagnostic and therapeutic potential miRNAs as novel ROP biomarkers.

Plasma miRNAs were evaluated in premature infants with ROP and compared to preterm infants without ROP in a recent study using high-throughput quantitative real-time PCR [127]. Four out of 46 plasma miRNAs were significantly altered in ROP patients, with miR-23a and miR-200b-3p being upregulated and miR-27b-3p and miR-214-3p being downregulated [127]. miR-23a represses anti-angiogenic genes, such as sprouty2 (Spry2) and semaphorin6A (Sema6A), and Sema6D [97], and hence might be pro-angiogenic in ROP pathogenesis. Expression of miR-200b correlates with VEGF expression [128], and is an angiogenic regulator targeting Ets-1 in ECs [112]. On the other hand, miR-27b and miR-214 are anti-angiogenic factors as they inhibit VEGF family protein expression [129,130,131]. Dysregulation of these miRNAs in ROP is consistent with their potential roles in mediating pathological angiogenesis in ROP development.

Profiles of miRNAs are evaluated in several pre-clinical animal models of ROP. The miRNA expression patterns in different models vary widely, and may depend on a number of factors including animal species (mice vs. rats), the oxygen condition, time point of tissue collection, and analysis methods. Some miRNAs exhibit dramatically varied expression patterns in different models, including miR-126 [144,166], miR-145 [167,168], miR-150 [72,167,169], and miR-155 [170]. The function of these miRNAs as ocular angiogenic regulators are discussed in detail in the next section.

7. Dysregulated miRNAs in Experimental Models of Pathological Ocular Angiogenesis

Expression patterns of miRNAs were investigated in several animal models of ocular NV that mimic pathological features of human vascular eye diseases. Of particular relevance to this review is the oxygen-induced retinopathy (OIR) model, mimicking pathological retinal NV in ROP and DR, and the laser-induced CNV model, mimicking wet AMD. By exposing the newborn experimental animals (rodents, in most cases) to continuous hyperoxic or cycling oxygen conditions, the OIR model reliably reproduces the phenotypes of ROP—characterized by an initial phase of vaso-obliteration and a subsequent phase of hypoxia-induced NV [171,172]. As the current diabetic models fail to consistently develop proliferative retinopathy in rodents, the OIR model also serves as a platform to facilitate the investigation of the ischemic angiogenesis aspect of DR [57]. For wet AMD, the rodent model of laser-induced CNV is the most standard and widely used animal model for investigating many aspects of choroidal angiogenesis. In this model an argon laser is used to induce rupture of the Bruch’s membrane, which increases pro-angiogenic and inflammatory factors and stimulates new choroidal vessels growth into the laser-injured subretinal areas to form CNV [173,174,175]. The pioneering work in the laser-induced CNV and the OIR models has laid the experimental foundation for establishing the therapeutic value of anti-VEGF therapies as these are useful models for investigating the mechanisms of NV and evaluating novel anti-neovascular therapies [176,177], including the role of miRNAs. Some examples of well-characterized miRNAs that regulate pathological ocular angiogenesis in experimental models are reviewed here.

7.1. miR-126

miR-126 is one of the angiomiRs implicated in the regulation of angiogenic factors including VEGF and FGF for vascular growth, and regulates embryonic angiogenesis and cardiac angiogenesis [91,92]. miR-126 exhibits significant downregulation in the choroids of mice with laser-induced CNV [123], as well as in rodent OIR retinas and choroids [144,166]. Moreover, miR-126 knockout mice have vascular lesions in the peripheral areas of choroids in mature adults, delayed choroidal vascular development, and focal choroidal vascular atrophy in aged mice [178]. In OIR mice, miR-126 supplementation inhibits retinal neovascularization and blood-retinal barrier breakdown [144,179]. Overall these findings indicate that miR-126 is required for maintaining ocular vasculature integrity in pathological conditions.

7.2. miR-132

In the mouse models, miR-132 plays a crucial role in promoting angiogenesis by targeting Rasa1 (encoding p120RasGAP) [180,181,182,183]. Inhibition of miR-132 in the mouse models of OIR and retinal angiomatous proliferation (RAP) promotes EC quiescence and prevents NV by enhancing the expression of p120RasGAP [181]. Inhibition of miR-132 reduces EC function and suppresses growth factor-mediated developmental retinal and tumor angiogenesis in vivo and in vitro [182]. Furthermore, silencing miR-132 also suppresses corneal angiogenesis after eye infection with herpes simplex virus [184]. Beyond vascular endothelium, miR-132 is also expressed in the eye by RGCs and is up-regulated in response to BDNF [78]. These findings suggest the angiogenic functions of miR-132 in neovascular ocular diseases and its additional function in retinal neuronal health.

7.3. miR-145

miR-145 is co-transcribed with miR-143 as a cluster, which is generally considered as a tumor suppressor cluster in cancer cells [185]. However, in the mouse model of lung adenocarcinoma, tumor-specific deletion of miR-143/145 resulted in diminished angiogenesis; whereas overexpression of miR-143/145 stimulated EC proliferation in the tumor mass [186], indicating a surprising pro-tumor and pro-angiogenic function of miR-143/145, likely reflecting its diverse role in a context-dependent manner. Mice with systemic knockout of miR-143/145 are viable and show no overt abnormalities in cardiac structure and vascular smooth muscle cell differentiation [187]. In the OIR model, miR-145 is significantly upregulated in the retinas at P17 when compared to the age-matched normoxic control mice [167]. Intravitreal injection of miR-145 inhibitors suppresses NV in OIR. Moreover, modulation of miR-145 in vitro alters human retinal microvascular endothelial cell (HRMEC) angiogenic functions by targeting tropomodulin 3 (Tmod3), an actin-capping protein. miR-145 may thereby influence angiogenesis in ocular neovascular diseases through the modulation of the cytoskeletal architecture dynamics, and EC morphological changes [168] (Figure 3). Other studies also showed that miR-145 in retinal ECs may attenuate oxidative stress and inflammation induced by high-glucose, further supporting its role in DR [188]. Within the eye, miR-143/145 cluster also regulates intraocular pressure through the regulation of actin dynamics and trabecular meshwork contractility [189]. miR-145 also promotes ganglion cell survival in DR [190]. These findings demonstrate multiple roles of miR-143/145 in various ocular cell types and eye diseases.

7.4. miR-146a

mR-146a has been linked to the innate immune response, inflammation, and age-related neurodegenerative disorders [191]. Samples from patients with wet AMD and mouse retinas with selective glial cell ablation showed an upregulation of miR-146a and an involvement in CFH-mediated inflammation [124,125]. In the pre-clinical models of DR, miR-146a is upregulated in the retinal ECs with transactivation by nuclear factor-kappaB (NF-κB). Upregulation of miR-146a exerts negative regulation in multiple pathways of NF-κB activation, which suggests its correlation to inflammatory responses in DR [148,192,193,194,195,196,197]. Specifically, miR-146a upregulates inflammatory cytokines in the diabetic retina and kidney [197], protects HRMECs [194], reduces retinal microvascular leakage, and improves visual function in diabetic rats [198]. Moreover, diabetes induces rhythmic dysregulation of miR-146a and its inflammatory genes in human retinal endothelial cells [195]. These findings all point to the potential implication of miR-146a in DR development.

7.5. miR-150

miR-150 is a well-studied miRNA which was initially identified by its regulatory effects in lymphocyte development and differentiation [199,200,201]. Monocytic-secreted miR-150 influences angiogenesis in cancer and diabetes by modulating target gene expression in recipient ECs [202,203]. In the retina, miR-150 is enriched in retinal ECs more than in any other nuclear layers [169]. In OIR, miR-150 is substantially reduced in OIR mouse retinas with specific downregulation in OIR neovessels, and regulates expression of several angiogenic factors, such as Cxcr4 (C-X-C chemokine receptor type 4), Dll4 (Delta like ligand 4) and Fzd4 (Frizzled-4) [72,169] (Figure 3). Treatment of miR-150 in vivo, via intraocular injection into the OIR mice, or in vitro, by transfection into HRMECs, demonstrated that miR-150 reduces pathological NV and regulates EC angiogenic functions in a VEGF-independent manner by targeting CXCR4, DLL4, and FZD4 [169]. Furthermore, miR-150 knockout mice show increased size of laser-induced CNV lesion [169], suggesting the role of miR-150 as an intrinsic inhibitor of pathological ocular angiogenesis. Similarly, miR-150 deletion leads to increased pulmonary angiogenesis in a hyperoxia-induced lung injury model [204], and exacerbates high fat diet-induced retinal NV in diabetic mice [149], suggesting an overall protective role of miR-150 against pathological angiogenesis.

7.6. miR-155

miR-155 is significantly upregulated in retinas of several ocular disease models, including the mouse OIR model [167,170], the rat models of light-induced retinal degeneration [205] and streptozotocin (STZ) -induced diabetes [148], as well as in human patients with AMD [124]. miR-155 is a HIF-dependent miRNA and its deficiency results in the reduction of the avascular area and NV in the mouse OIR model [150,170]. By targeting CCN1—a cysteine-rich and integrin-binding matricellular protein, upregulated miR-155 disturbs the normal retinal vessel growth in mice [170]. In addition to regulation of angiogenesis, miR-155 is also involved in inflammatory and immunomodulatory signaling pathways, which are of crucial importance in pathological angiogenesis [206]. In the preclinical model of STZ-induced DR, miR-155 was identified as a NF-κB- and VEGF-responsive miRNA [148]. miR-155 has also been shown to regulate CFH in AMD [124], further supporting its role in ocular angiogenesis and inflammation in eye diseases.

7.7. miR-21

miR-21 plays an important role in the regulation of angiogenesis, tumor growth and metastasis, as well as in cardiac hypertrophy [126,148,207,208]. This miRNA is downregulated in the plasma of wet AMD patients [118]. As such, miR-21 may play an important role in AMD pathogenesis for its involvement in the regulation of vascular growth, as exhibited by its high expression in retinal ECs [126]. This notion is supported by the fact that overexpression of miR-21 reduces CNV lesions in the laser-induced CNV mice. In addition, stimulated expression of miR-21 inhibits cultured EC proliferation and migration by targeted inhibition of RhoB, which controls the dynamics of actin-filament and thereby affects the EC function [126]. However, in the rat diabetic model, miR-21, as well as miR-146 and miR-155, are upregulated in the retinas and retinal ECs along with NF-κB and/or VEGF activation [148]. In the retinas of leptin receptor-deficient (db/db) mice, miR-21 was also significantly upregulated while its target gene PPARα (peroxisome proliferator-activated receptor-α), was downregulated [209]. These different findings from several animal models may reflect an underlying difference among various eye disease models or assay conditions, yet together indicate a potential disease-modifying effect of miR-21.

8. Conclusions

In summary, miRNAs are potent effectors in the post-transcriptional regulation of gene activity and play an important role in the modulation of retinal homeostasis and diseases including vascular eye diseases. Although the miRNA expression profiles from different experimental models of ocular angiogenesis differ in a disease- and model-dependent manner, these studies provide valuable clues to understanding the functions of dysregulated miRNAs in retinopathies. Furthermore, dysregulation of specific miRNAs can be utilized to identify potential miRNA candidates for therapeutic intervention. With expanding knowledge of miRNA profiles and their molecular mechanisms in eye development and ocular diseases, miRNAs can be harnessed for their capacities as biomarkers and their potential to be targeted for treating neovascular ocular diseases. In fact, the emerging miRNA therapeutics with its ability to target multiple pathological target genes may likely yield one of the most exciting breakthroughs in the current treatment options for ocular diseases. With the current surge in omics research providing vast amounts of datasets, identification of critical miRNA targets for drug development presents considerable potential for generating such novel therapies for vascular eye diseases.

Competing interests

Conflicts of InterestThe authors declare no conflict of interest.

References

1. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J. et al. Initial sequencing and analysis of the human genome. Nature. 2001 doi:10.1038/35057062 PubMed
2. Finishing the euchromatic sequence of the human genome. Nature. 2004 doi:10.1038/nature03001 PubMed
3. Lee R.C., Feinbaum R.L., Ambros V.. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 doi:10.1016/0092-8674(93)90529-Y PubMed
4. He L., Hannon G.J.. MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet.. 2004 doi:10.1038/nrg1379 PubMed
5. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P.. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res.. 2009 doi:10.1101/gr.082701.108 PubMed
6. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M.. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003 doi:10.1016/S0092-8674(03)00231-9 PubMed
7. Chang T.C., Mendell J.T.. microRNAs in vertebrate physiology and human disease. Annu. Rev. Genom. Hum. Genet.. 2007 doi:10.1146/annurev.genom.8.080706.092351 PubMed
8. Im H.I., Kenny P.J.. MicroRNAs in neuronal function and dysfunction. Trends Neurosci.. 2012 doi:10.1016/j.tins.2012.01.004 PubMed
9. Du L., Pertsemlidis A.. Cancer and neurodegenerative disorders: Pathogenic convergence through microRNA regulation. J. Mol. Cell Biol.. 2011 doi:10.1093/jmcb/mjq058 PubMed
10. Nicoli S., Standley C., Walker P., Hurlstone A., Fogarty K.E., Lawson N.D.. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature. 2010 doi:10.1038/nature08889 PubMed
11. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J.. 2004 doi:10.1038/sj.emboj.7600385 PubMed
12. Han J., Lee Y., Yeom K.H., Kim Y.K., Jin H., Kim V.N.. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev.. 2004 doi:10.1101/gad.1262504 PubMed
13. Han J., Lee Y., Yeom K.H., Nam J.W., Heo I., Rhee J.K. et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006 doi:10.1016/j.cell.2006.03.043 PubMed
14. Lund E., Guttinger S., Calado A., Dahlberg J.E., Kutay U.. Nuclear export of microRNA precursors. Science. 2004 doi:10.1126/science.1090599 PubMed
15. Yi R., Qin Y., Macara I.G., Cullen B.R.. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev.. 2003 doi:10.1101/gad.1158803 PubMed
16. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., Zamore P.D.. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001 doi:10.1126/science.1062961 PubMed
17. Khvorova A., Reynolds A., Jayasena S.D.. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003 doi:10.1016/S0092-8674(03)00801-8 PubMed
18. Schwarz D.S., Hutvagner G., Du T., Xu Z., Aronin N., Zamore P.D.. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003 doi:10.1016/S0092-8674(03)00759-1 PubMed
19. Krol J., Loedige I., Filipowicz W.. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet.. 2010 doi:10.1038/nrg2843 PubMed
20. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 2002 doi:10.1073/pnas.242606799 PubMed
21. Pogribny I.P.. MicroRNAs as biomarkers for clinical studies. Exp. Biol. Med.. 2018 doi:10.1177/1535370217731291 PubMed
22. Rashed W.M., Hamza M.M., Matboli M., Salem S.I.. MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: A systematic review. Cancer Metastasis Rev.. 2019 doi:10.1007/s10555-019-09826-0 PubMed
23. Zhang Y., Li X., Bai L., Li L., Li D., Ding X. et al. MicroRNA-31 is a potential biomarker for screening B-lymphoblastic leukemia in children. Oncol. Lett.. 2019 doi:10.3892/ol.2019.10843 PubMed
24. Guo Y.. Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia. Bioengineered. 2019 doi:10.1080/21655979.2019.1652490 PubMed
25. Fathullahzadeh S., Mirzaei H., Honardoost M.A., Sahebkar A., Salehi M.. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther.. 2016 doi:10.1038/cgt.2016.34 PubMed
26. Yeh C.H., Moles R., Nicot C.. Clinical significance of microRNAs in chronic and acute human leukemia. Mol. Cancer. 2016 doi:10.1186/s12943-016-0518-2 PubMed
27. Giza D.E., Calin G.A.. microRNA and Chronic Lymphocytic Leukemia. Adv. Exp. Med. Biol.. 2015 doi:10.1007/978-3-319-23730-5_2 PubMed
28. Tavakolian S., Goudarzi H., Torfi F., Faghihloo E.. Evaluation of microRNA-9 and -192 expression levels as biomarkers in patients suffering from breast cancer. Biomed. Rep.. 2020 doi:10.3892/br.2019.1257 PubMed
29. Al-Othman N., Ahram M., Alqaraleh M.. Role of androgen and microRNA in triple-negative breast cancer. Breast Dis.. 2019 doi:10.3233/BD-190416 PubMed
30. Liu B., Su F., Lv X., Zhang W., Shang X., Zhang Y. et al. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemother. Pharmacol.. 2019 doi:10.1007/s00280-019-03937-9 PubMed
31. Zhang J., Yang J., Zhang X., Xu J., Sun Y., Zhang P.. MicroRNA-10b expression in breast cancer and its clinical association. PLoS ONE. 2018 doi:10.1371/journal.pone.0192509 PubMed
32. Tahiri A., Aure M.R., Kristensen V.N.. MicroRNA Networks in Breast Cancer Cells. Methods Mol. Biol.. 2018 doi:10.1007/978-1-4939-7493-1_4 PubMed
33. Kang S.M., Lee H.J.. MicroRNAs in human lung cancer. Exp. Biol. Med.. 2014 doi:10.1177/1535370214533887 PubMed
34. Jeong H.C.. Clinical Aspect of MicroRNA in Lung Cancer. Tuberc. Respir. Dis.. 2014 doi:10.4046/trd.2014.77.2.60 PubMed
35. Wang Y., Zhang X., Liu L., Li H., Yu J., Wang C. et al. Clinical implication of microrna for lung cancer. Cancer Biother. Radiopharm.. 2013 doi:10.1089/cbr.2012.1401 PubMed
36. Markou A., Sourvinou I., Vorkas P.A., Yousef G.M., Lianidou E.. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013 doi:10.1016/j.lungcan.2013.05.007 PubMed
37. Lee J.H., Voortman J., Dingemans A.M., Voeller D.M., Pham T., Wang Y. et al. MicroRNA expression and clinical outcome of small cell lung cancer. PLoS ONE. 2011 doi:10.1371/journal.pone.0021300 PubMed
38. Di Leva G., Garofalo M., Croce C.M.. MicroRNAs in cancer. Annu. Rev. Pathol.. 2014 doi:10.1146/annurev-pathol-012513-104715 PubMed
39. Navickas R., Gal D., Laucevicius A., Taparauskaite A., Zdanyte M., Holvoet P.. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc. Res.. 2016 doi:10.1093/cvr/cvw174 PubMed
40. Dong H., Wang C., Lu S., Yu C., Huang L., Feng W. et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease. Biomark. Biochem. Indic. Expo. Response Susceptibility Chem.. 2016 doi:10.3109/1354750X.2015.1118544 PubMed
41. Mencia A., Modamio-Hoybjor S., Redshaw N., Morin M., Mayo-Merino F., Olavarrieta L. et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat. Genet.. 2009 doi:10.1038/ng.355 PubMed
42. Hughes A.E., Bradley D.T., Campbell M., Lechner J., Dash D.P., Simpson D.A. et al. Mutation altering the miR-184 seed region causes familial keratoconus with cataract. Am. J. Hum. Genet.. 2011 doi:10.1016/j.ajhg.2011.09.014 PubMed
43. De Pontual L., Yao E., Callier P., Faivre L., Drouin V., Cariou S. et al. Germline deletion of the miR-17 approximately 92 cluster causes skeletal and growth defects in humans. Nat. Genet.. 2011 doi:10.1038/ng.915 PubMed
44. Reh T.A., Hindges R.. MicroRNAs in Retinal Development. Annu Rev. Vis. Sci.. 2018 doi:10.1146/annurev-vision-091517-034357 PubMed
45. Karali M., Banfi S.. Non-coding RNAs in retinal development and function. Hum. Genet.. 2019 doi:10.1007/s00439-018-1931-y PubMed
46. Zuzic M., Rojo Arias J.E., Wohl S.G., Busskamp V.. Retinal miRNA Functions in Health and Disease. Genes. 2019 doi:10.3390/genes10050377 PubMed
47. Akhtar S., Patnaik S.R., Kotapati Raghupathy R., Al-Mubrad T.M., Craft J.A., Shu X.. Histological Characterization of the Dicer1 Mutant Zebrafish Retina. J. Ophthalmol.. 2015 doi:10.1155/2015/309510 PubMed
48. Decembrini S., Bressan D., Vignali R., Pitto L., Mariotti S., Rainaldi G. et al. MicroRNAs couple cell fate and developmental timing in retina. Proc. Natl. Acad. Sci. USA. 2009 doi:10.1073/pnas.0909167106 PubMed
49. Davis N., Mor E., Ashery-Padan R.. Roles for Dicer1 in the patterning and differentiation of the optic cup neuroepithelium. Development. 2011 doi:10.1242/dev.053637 PubMed
50. Damiani D., Alexander J.J., O’Rourke J.R., McManus M., Jadhav A.P., Cepko C.L. et al. Dicer inactivation leads to progressive functional and structural degeneration of the mouse retina. J. Neurosci.. 2008 doi:10.1523/JNEUROSCI.0828-08.2008 PubMed
51. Georgi S.A., Reh T.A.. Dicer is required for the transition from early to late progenitor state in the developing mouse retina. J. Neurosci.. 2010 doi:10.1523/JNEUROSCI.4982-09.2010 PubMed
52. Hackler L., Wan J., Swaroop A., Qian J., Zack D.J.. MicroRNA profile of the developing mouse retina. Investig. Ophthalmol. Vis. Sci.. 2010 doi:10.1167/iovs.09-4657 PubMed
53. Iida A., Shinoe T., Baba Y., Mano H., Watanabe S.. Dicer plays essential roles for retinal development by regulation of survival and differentiation. Investig. Ophthalmol. Vis. Sci.. 2011 doi:10.1167/iovs.10-6428 PubMed
54. La Torre A., Georgi S., Reh T.A.. Conserved microRNA pathway regulates developmental timing of retinal neurogenesis. Proc. Natl. Acad. Sci. USA. 2013 doi:10.1073/pnas.1301837110 PubMed
55. Maiorano N.A., Hindges R.. Restricted perinatal retinal degeneration induces retina reshaping and correlated structural rearrangement of the retinotopic map. Nat. Commun.. 2013 doi:10.1038/ncomms2926 PubMed
56. Pinter R., Hindges R.. Perturbations of microRNA function in mouse dicer mutants produce retinal defects and lead to aberrant axon pathfinding at the optic chiasm. PLoS ONE. 2010 doi:10.1371/journal.pone.0010021 PubMed
57. Liu C.H., Wang Z., Sun Y., Chen J.. Animal models of ocular angiogenesis: From development to pathologies. FASEB J.. 2017 doi:10.1096/fj.201700336R PubMed
58. Arora A., Guduric-Fuchs J., Harwood L., Dellett M., Cogliati T., Simpson D.A.. Prediction of microRNAs affecting mRNA expression during retinal development. BMC Dev. Biol.. 2010 doi:10.1186/1471-213X-10-1 PubMed
59. Deo M., Yu J.Y., Chung K.H., Tippens M., Turner D.L.. Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev. Dyn.. 2006 doi:10.1002/dvdy.20847 PubMed
60. Karali M., Peluso I., Gennarino V.A., Bilio M., Verde R., Lago G. et al. miRNeye: A microRNA expression atlas of the mouse eye. BMC Genom.. 2010 doi:10.1186/1471-2164-11-715 PubMed
61. Karali M., Peluso I., Marigo V., Banfi S.. Identification and characterization of microRNAs expressed in the mouse eye. Investig. Ophthalmol. Vis. Sci.. 2007 doi:10.1167/iovs.06-0866 PubMed
62. Adijanto J., Castorino J.J., Wang Z.X., Maminishkis A., Grunwald G.B., Philp N.J.. Microphthalmia-associated transcription factor (MITF) promotes differentiation of human retinal pigment epithelium (RPE) by regulating microRNAs-204/211 expression. J. Biol. Chem.. 2012 doi:10.1074/jbc.M112.354761 PubMed
63. Conte I., Carrella S., Avellino R., Karali M., Marco-Ferreres R., Bovolenta P. et al. miR-204 is required for lens and retinal development via Meis2 targeting. Proc. Natl. Acad. Sci. USA. 2010 doi:10.1073/pnas.0914785107 PubMed
64. Sanuki R., Onishi A., Koike C., Muramatsu R., Watanabe S., Muranishi Y. et al. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat. Neurosci.. 2011 doi:10.1038/nn.2897 PubMed
65. Karali M., Persico M., Mutarelli M., Carissimo A., Pizzo M., Singh Marwah V. et al. High-resolution analysis of the human retina miRNome reveals isomiR variations and novel microRNAs. Nucleic Acids Res.. 2016 doi:10.1093/nar/gkw039 PubMed
66. Barbato S., Marrocco E., Intartaglia D., Pizzo M., Asteriti S., Naso F. et al. MiR-211 is essential for adult cone photoreceptor maintenance and visual function. Sci. Rep.. 2017 doi:10.1038/s41598-017-17331-z PubMed
67. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A. et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007 doi:10.1016/j.cell.2007.04.040 PubMed
68. Arora A., McKay G.J., Simpson D.A.. Prediction and verification of miRNA expression in human and rat retinas. Investig. Ophthalmol. Vis. Sci.. 2007 doi:10.1167/iovs.06-1221 PubMed
69. Kapsimali M., Kloosterman W.P., de Bruijn E., Rosa F., Plasterk R.H., Wilson S.W.. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol.. 2007 doi:10.1186/gb-2007-8-8-r173 PubMed
70. Makarev E., Spence J.R., Del Rio-Tsonis K., Tsonis P.A.. Identification of microRNAs and other small RNAs from the adult newt eye. Mol. Vis.. 2006 PubMed
71. Ryan D.G., Oliveira-Fernandes M., Lavker R.M.. MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. Mol. Vis.. 2006 PubMed
72. Shen J., Yang X., Xie B., Chen Y., Swaim M., Hackett S.F. et al. MicroRNAs regulate ocular neovascularization. Mol. Ther. J. Am. Soc. Gene Ther.. 2008 doi:10.1038/mt.2008.104 PubMed
73. Wohl S.G., Reh T.A.. The microRNA expression profile of mouse Muller glia in vivo and in vitro. Sci. Rep.. 2016 doi:10.1038/srep35423 PubMed
74. Xu S., Witmer P.D., Lumayag S., Kovacs B., Valle D.. MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J. Biol. Chem.. 2007 doi:10.1074/jbc.M700501200 PubMed
75. Chu-Tan J.A., Rutar M., Saxena K., Aggio-Bruce R., Essex R.W., Valter K. et al. MicroRNA-124 Dysregulation is Associated with Retinal Inflammation and Photoreceptor Death in the Degenerating Retina. Investig. Ophthalmol. Vis. Sci.. 2018 doi:10.1167/iovs.18-24623 PubMed
76. Qian Y., Song J., Ouyang Y., Han Q., Chen W., Zhao X. et al. Advances in Roles of miR-132 in the Nervous System. Front. Pharmacol.. 2017 doi:10.3389/fphar.2017.00770 PubMed
77. Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010 doi:10.1016/j.neuron.2010.08.044 PubMed
78. Marler K.J., Suetterlin P., Dopplapudi A., Rubikaite A., Adnan J., Maiorano N.A. et al. BDNF promotes axon branching of retinal ganglion cells via miRNA-132 and p250GAP. J. Neurosci.. 2014 doi:10.1523/JNEUROSCI.1910-13.2014 PubMed
79. Folkman J.. Angiogenesis: An organizing principle for drug discovery?. Nat. Rev. Drug Discov.. 2007 doi:10.1038/nrd2115 PubMed
80. Sholley M.M., Ferguson G.P., Seibel H.R., Montour J.L., Wilson J.D.. Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. Lab. Invest.. 1984 PubMed
81. Carmeliet P.. Angiogenesis in life, disease and medicine. Nature. 2005 doi:10.1038/nature04478 PubMed
82. Apte R.S., Chen D.S., Ferrara N.. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019 doi:10.1016/j.cell.2019.01.021 PubMed
83. Afzal A., Shaw L.C., Ljubimov A.V., Boulton M.E., Segal M.S., Grant M.B.. Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvasc. Res.. 2007 doi:10.1016/j.mvr.2007.04.011 PubMed
84. Otsuka M., Zheng M., Hayashi M., Lee J.D., Yoshino O., Lin S. et al. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J. Clin. Invest.. 2008 doi:10.1172/JCI33680 PubMed
85. Yang W.J., Yang D.D., Na S., Sandusky G.E., Zhang Q., Zhao G.. Dicer is required for embryonic angiogenesis during mouse development. J. Biol. Chem.. 2005 doi:10.1074/jbc.M413394200 PubMed
86. Kuehbacher A., Urbich C., Zeiher A.M., Dimmeler S.. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res.. 2007 doi:10.1161/CIRCRESAHA.107.153916 PubMed
87. Suarez Y., Fernandez-Hernando C., Yu J., Gerber S.A., Harrison K.D., Pober J.S. et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. USA. 2008 doi:10.1073/pnas.0804597105 PubMed
88. Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K. et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006 doi:10.1182/blood-2006-01-012369 PubMed
89. Wang S., Olson E.N.. AngiomiRs—Key regulators of angiogenesis. Curr. Opin. Genet. Dev.. 2009 doi:10.1016/j.gde.2009.04.002 PubMed
90. Wakioka T., Sasaki A., Kato R., Shouda T., Matsumoto A., Miyoshi K. et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature. 2001 doi:10.1038/35088082 PubMed
91. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 2008 doi:10.1016/j.devcel.2008.07.002 PubMed
92. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D. et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell. 2008 doi:10.1016/j.devcel.2008.07.008 PubMed
93. Fasanaro P., D’Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G. et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem.. 2008 doi:10.1074/jbc.M800731200 PubMed
94. Fasanaro P., Greco S., Lorenzi M., Pescatori M., Brioschi M., Kulshreshtha R. et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J. Biol. Chem.. 2009 doi:10.1074/jbc.M109.052779 PubMed
95. Miao H., Wang B.. EphA receptor signaling—Complexity and emerging themes. Semin. Cell Dev. Biol.. 2012 doi:10.1016/j.semcdb.2011.10.013 PubMed
96. Larson J., Schomberg S., Schroeder W., Carpenter T.C.. Endothelial EphA receptor stimulation increases lung vascular permeability. Am. J. Physiol. Lung Cell Mol. Physiol.. 2008 doi:10.1152/ajplung.90256.2008 PubMed
97. Zhou Q., Gallagher R., Ufret-Vincenty R., Li X., Olson E.N., Wang S.. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc. Natl. Acad. Sci. USA. 2011 doi:10.1073/pnas.1105254108 PubMed
98. Fiedler J., Jazbutyte V., Kirchmaier B.C., Gupta S.K., Lorenzen J., Hartmann D. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011 doi:10.1161/CIRCULATIONAHA.111.039008 PubMed
99. Oikawa S., Wada S., Lee M., Maeda S., Akimoto T.. Role of endothelial microRNA-23 clusters in angiogenesis in vivo. Am. J. Physiol. Heart Circ. Physiol.. 2018 doi:10.1152/ajpheart.00742.2017 PubMed
100. Li J., Zhao Y., Lu Y., Ritchie W., Grau G., Vadas M.A. et al. The Poly-cistronic miR-23-27-24 Complexes Target Endothelial Cell Junctions: Differential Functional and Molecular Effects of miR-23a and miR-23b. Mol. Ther. Nucleic Acids. 2016 doi:10.1038/mtna.2016.62 PubMed
101. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A. et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009 doi:10.1126/science.1174381 PubMed
102. Chamorro-Jorganes A., Lee M.Y., Araldi E., Landskroner-Eiger S., Fernandez-Fuertes M., Sahraei M. et al. VEGF-Induced Expression of miR-17-92 Cluster in Endothelial Cells Is Mediated by ERK/ELK1 Activation and Regulates Angiogenesis. Circ. Res.. 2016 doi:10.1161/CIRCRESAHA.115.307408 PubMed
103. Landskroner-Eiger S., Qiu C., Perrotta P., Siragusa M., Lee M.Y., Ulrich V. et al. Endothelial miR-17 approximately 92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Proc. Natl. Acad. Sci. USA. 2015 doi:10.1073/pnas.1507094112 PubMed
104. Hua Z., Lv Q., Ye W., Wong C.K., Cai G., Gu D. et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE. 2006 doi:10.1371/journal.pone.0000116 PubMed
105. Qin L.L., An M.X., Liu Y.L., Xu H.C., Lu Z.Q.. MicroRNA-126: A promising novel biomarker in peripheral blood for diabetic retinopathy. Int. J. Ophthalmol.. 2017 doi:10.18240/ijo.2017.04.05 PubMed
106. Barutta F., Bruno G., Matullo G., Chaturvedi N., Grimaldi S., Schalkwijk C. et al. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. Acta Diabetol.. 2017 doi:10.1007/s00592-016-0915-4 PubMed
107. Rezk N.A., Sabbah N.A., Saad M.S.. Role of MicroRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life. 2016 doi:10.1002/iub.1502 PubMed
108. Kuhnert F., Mancuso M.R., Hampton J., Stankunas K., Asano T., Chen C.Z. et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 2008 doi:10.1242/dev.029736 PubMed
109. Mazzeo A., Beltramo E., Lopatina T., Gai C., Trento M., Porta M.. Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects. Exp. Eye Res.. 2018 doi:10.1016/j.exer.2018.07.003 PubMed
110. Yang T.T., Song S.J., Xue H.B., Shi D.F., Liu C.M., Liu H.. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. Eur. Rev. Med. Pharmacol. Sci.. 2015 PubMed
111. Li E.H., Huang Q.Z., Li G.C., Xiang Z.Y., Zhang X.. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene. Biosci. Rep.. 2017 doi:10.1042/BSR20160572 PubMed
112. Chan Y.C., Khanna S., Roy S., Sen C.K.. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J. Biol. Chem.. 2011 doi:10.1074/jbc.M110.158790 PubMed
113. Liu H.N., Li X., Wu N., Tong M.M., Chen S., Zhu S.S. et al. Serum microRNA-221 as a biomarker for diabetic retinopathy in patients associated with type 2 diabetes. Int J. Ophthalmol.. 2018 doi:10.18240/ijo.2018.12.02 PubMed
114. Fiorentino L., Cavalera M., Mavilio M., Conserva F., Menghini R., Gesualdo L. et al. Regulation of TIMP3 in diabetic nephropathy: A role for microRNAs. Acta Diabetol.. 2013 doi:10.1007/s00592-013-0492-8 PubMed
115. Costantino S., Paneni F., Luscher T.F., Cosentino F.. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. Eur. Heart J.. 2016 doi:10.1093/eurheartj/ehv599 PubMed
116. Lightell D.J., Moss S.C., Woods T.C.. Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus. Atherosclerosis. 2018 doi:10.1016/j.atherosclerosis.2017.12.016 PubMed
117. Zampetaki A., Willeit P., Burr S., Yin X., Langley S.R., Kiechl S. et al. Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. Diabetes. 2016 doi:10.2337/db15-0389 PubMed
118. Ertekin S., Yildirim O., Dinc E., Ayaz L., Fidanci S.B., Tamer L.. Evaluation of circulating miRNAs in wet age-related macular degeneration. Mol. Vis.. 2014 PubMed
119. Szemraj M., Bielecka-Kowalska A., Oszajca K., Krajewska M., Gos R., Jurowski P. et al. Serum MicroRNAs as Potential Biomarkers of AMD. Med. Sci. Monit.. 2015 doi:10.12659/MSM.893697 PubMed
120. Chen Z., Lai T.C., Jan Y.H., Lin F.M., Wang W.C., Xiao H. et al. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J. Clin. Invest.. 2013 doi:10.1172/JCI65344 PubMed
121. Romano G.L., Platania C.B.M., Drago F., Salomone S., Ragusa M., Barbagallo C. et al. Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Front. Pharmacol.. 2017 doi:10.3389/fphar.2017.00168 PubMed
122. Zhou Q., Anderson C., Hanus J., Zhao F., Ma J., Yoshimura A. et al. Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis. Mol. Ther. J. Am. Soc. Gene Ther.. 2016 doi:10.1038/mt.2016.108 PubMed
123. Wang L., Lee A.Y., Wigg J.P., Peshavariya H., Liu P., Zhang H.. miR-126 Regulation of Angiogenesis in Age-Related Macular Degeneration in CNV Mouse Model. Int. J. Mol. Sci.. 2016 doi:10.3390/ijms17060895 PubMed
124. Lukiw W.J., Surjyadipta B., Dua P., Alexandrov P.N.. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in age-related macular degeneration (AMD). Int. J. Biochem. Mol. Biol.. 2012 PubMed
125. Kutty R.K., Nagineni C.N., Samuel W., Vijayasarathy C., Jaworski C., Duncan T. et al. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment epithelial cells by interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma. Mol. Vis.. 2013 PubMed
126. Sabatel C., Malvaux L., Bovy N., Deroanne C., Lambert V., Gonzalez M.L. et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS ONE. 2011 doi:10.1371/journal.pone.0016979 PubMed
127. Metin T., Dinc E., Gorur A., Erdogan S., Ertekin S., Sari A.A. et al. Evaluation of the plasma microRNA levels in stage 3 premature retinopathy with plus disease: Preliminary study. Eye. 2018 doi:10.1038/eye.2017.193 PubMed
128. Zhao R., Qian L., Jiang L.. Identification of retinopathy of prematurity related miRNAs in hyperoxia-induced neonatal rats by deep sequencing. Int. J. Mol. Sci.. 2014 doi:10.3390/ijms16010840 PubMed
129. Ye J., Wu X., Wu D., Wu P., Ni C., Zhang Z. et al. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS ONE. 2013 doi:10.1371/journal.pone.0060687 PubMed
130. Liu H.T., Xing A.Y., Chen X., Ma R.R., Wang Y.W., Shi D.B. et al. MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget. 2015 doi:10.18632/oncotarget.6059 PubMed
131. Van Mil A., Grundmann S., Goumans M.J., Lei Z., Oerlemans M.I., Jaksani S. et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc. Res.. 2012 doi:10.1093/cvr/cvs003 PubMed
132. Morello C.M.. Etiology and natural history of diabetic retinopathy: An overview. Am. J. Health-Syst. Pharm.. 2007 doi:10.2146/ajhp070330 PubMed
133. Paulus Y.M., Gariano R.F.. Diabetic retinopathy: A growing concern in an aging population. Geriatrics. 2009 PubMed
134. De La Cruz J.P., Gonzalez-Correa J.A., Guerrero A., de la Cuesta F.S.. Pharmacological approach to diabetic retinopathy. Diabetes Metab. Res. Rev.. 2004 doi:10.1002/dmrr.432 PubMed
135. Fong D.S., Aiello L.P., Ferris F.L., Klein R.. Diabetic retinopathy. Diabetes Care. 2004 doi:10.2337/diacare.27.10.2540 PubMed
136. Stitt A.W., Curtis T.M., Chen M., Medina R.J., McKay G.J., Jenkins A. et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res.. 2016 doi:10.1016/j.preteyeres.2015.08.001 PubMed
137. Qazi Y., Maddula S., Ambati B.K.. Mediators of ocular angiogenesis. J. Genet.. 2009 doi:10.1007/s12041-009-0068-0 PubMed
138. Sivaprasad S., Gupta B., Crosby-Nwaobi R., Evans J.. Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Surv. Ophthalmol.. 2012 doi:10.1016/j.survophthal.2012.01.004 PubMed
139. Jimenez-Lucena R., Camargo A., Alcala-Diaz J.F., Romero-Baldonado C., Luque R.M., van Ommen B. et al. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: From the CORDIOPREV study. Exp. Mol. Med.. 2018 doi:10.1038/s12276-018-0194-y PubMed
140. Jimenez-Lucena R., Rangel-Zuniga O.A., Alcala-Diaz J.F., Lopez-Moreno J., Roncero-Ramos I., Molina-Abril H. et al. Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study. Mol. Ther. Nucleic Acids. 2018 doi:10.1016/j.omtn.2018.05.002 PubMed
141. Barutta F., Bellini S., Mastrocola R., Bruno G., Gruden G.. MicroRNA and Microvascular Complications of Diabetes. Int. J. Endocrinol.. 2018 doi:10.1155/2018/6890501 PubMed
142. Qing S., Yuan S., Yun C., Hui H., Mao P., Wen F. et al. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol. Biochem.. 2014 doi:10.1159/000366374 PubMed
143. Ye P., Liu J., He F., Xu W., Yao K.. Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int. J. Med. Sci.. 2014 doi:10.7150/ijms.7329 PubMed
144. Bai Y., Bai X., Wang Z., Zhang X., Ruan C., Miao J.. MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp. Mol. Pathol.. 2011 doi:10.1016/j.yexmp.2011.04.016 PubMed
145. Wang Y., Yan H.. MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy. Sci. Rep.. 2016 doi:10.1038/srep26909 PubMed
146. McArthur K., Feng B., Wu Y., Chen S., Chakrabarti S.. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011 doi:10.2337/db10-1557 PubMed
147. McAuley A.K., Dirani M., Wang J.J., Connell P.P., Lamoureux E.L., Hewitt A.W.. A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy. Diab. Vasc. Dis. Res.. 2015 doi:10.1177/1479164114560160 PubMed
148. Kovacs B., Lumayag S., Cowan C., Xu S.. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Investig. Ophthalmol. Vis. Sci.. 2011 doi:10.1167/iovs.10-6879 PubMed
149. Shi L., Kim A.J., Chang R.C., Chang J.Y., Ying W., Ko M.L. et al. Deletion of miR-150 Exacerbates Retinal Vascular Overgrowth in High-Fat-Diet Induced Diabetic Mice. PLoS ONE. 2016 doi:10.1371/journal.pone.0157543 PubMed
150. Zhuang Z., Xiao q., Hu H., Tian S.Y., Lu Z.J., Zhang T.Z. et al. Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway. Mol. Vis.. 2015 PubMed
151. Gomaa A.R., Elsayed E.T., Moftah R.F.. MicroRNA-200b Expression in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. Ophthalmic Res.. 2017 doi:10.1159/000475671 PubMed
152. Murray A.R., Chen Q., Takahashi Y., Zhou K.K., Park K., Ma J.X.. MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Investig. Ophthalmol. Vis. Sci.. 2013 doi:10.1167/iovs.12-10921 PubMed
153. Friedman E.. The pathogenesis of age-related macular degeneration. Am. J. Ophthalmol.. 2008 doi:10.1016/j.ajo.2008.05.017 PubMed
154. Jager R.D., Mieler W.F., Miller J.W.. Age-related macular degeneration. N. Eng. J. Med.. 2008 doi:10.1056/NEJMra0801537 PubMed
155. Coleman H.R., Chan C.C., Ferris F.L., Chew E.Y.. Age-related macular degeneration. Lancet. 2008 doi:10.1016/S0140-6736(08)61759-6 PubMed
156. Grassmann F., Schoenberger P.G., Brandl C., Schick T., Hasler D., Meister G. et al. A circulating microrna profile is associated with late-stage neovascular age-related macular degeneration. PLoS ONE. 2014 doi:10.1371/journal.pone.0107461 PubMed
157. Menard C., Rezende F.A., Miloudi K., Wilson A., Tetreault N., Hardy P. et al. MicroRNA signatures in vitreous humour and plasma of patients with exudative AMD. Oncotarget. 2016 doi:10.18632/oncotarget.8280 PubMed
158. Good W.V.. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans. Am. Ophthalmol. Soc.. 2004 PubMed
159. Tasman W., Patz A., McNamara J.A., Kaiser R.S., Trese M.T., Smith B.T.. Retinopathy of prematurity: The life of a lifetime disease. Am. J. Ophthalmol.. 2006 doi:10.1016/j.ajo.2005.07.034 PubMed
160. Gilbert C., Rahi J., Eckstein M., O’Sullivan J., Foster A.. Retinopathy of prematurity in middle-income countries. Lancet. 1997 doi:10.1016/S0140-6736(97)01107-0 PubMed
161. Chen J., Smith L.E.. Retinopathy of prematurity. Angiogenesis. 2007 doi:10.1007/s10456-007-9066-0 PubMed
162. Hartnett M.E., Penn J.S.. Mechanisms and management of retinopathy of prematurity. N. Eng. J. Med.. 2012 doi:10.1056/NEJMra1208129 PubMed
163. Hellstrom A., Smith L.E., Dammann O.. Retinopathy of prematurity. Lancet. 2013 doi:10.1016/S0140-6736(13)60178-6 PubMed
164. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Ophthalmological outcomes at 10 years. Arch. Ophthalmol.. 2001 doi:10.1001/archopht.119.8.1110 PubMed
165. Wallace D.K., Wu K.Y.. Current and future trends in treatment of severe retinopathy of prematurity. Clin. Perinatal.. 2013 doi:10.1016/j.clp.2013.02.005 PubMed
166. Desjarlais M., Rivera J.C., Lahaie I., Cagnone G., Wirt M., Omri S. et al. MicroRNA expression profile in retina and choroid in oxygen-induced retinopathy model. PLoS ONE. 2019 doi:10.1371/journal.pone.0218282 PubMed
167. Liu C.H., Wang Z., Sun Y., SanGiovanni J.P., Chen J.. Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy. Sci. Rep.. 2016 doi:10.1038/srep33947 PubMed
168. Liu C.H., Wang Z., Huang S., Sun Y., Chen J.. MicroRNA-145 Regulates Pathological Retinal Angiogenesis by Suppression of TMOD3. Mol. Ther. Nucleic Acids. 2019 doi:10.1016/j.omtn.2019.03.001 PubMed
169. Liu C.H., Sun Y., Li J., Gong Y., Tian K.T., Evans L.P. et al. Endothelial microRNA-150 is an intrinsic suppressor of pathologic ocular neovascularization. Proc. Natl. Acad. Sci. USA. 2015 doi:10.1073/pnas.1508426112 PubMed
170. Yan L., Lee S., Lazzaro D.R., Aranda J., Grant M.B., Chaqour B.. Single and Compound Knock-outs of MicroRNA (miRNA)-155 and Its Angiogenic Gene Target CCN1 in Mice Alter Vascular and Neovascular Growth in the Retina via Resident Microglia. J. Biol. Chem.. 2015 doi:10.1074/jbc.M115.646950 PubMed
171. Penn J.S., Tolman B.L., Lowery L.A.. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Investig. Ophthalmol. Vis. Sci.. 1993 PubMed
172. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D’Amato R., Sullivan R. et al. Oxygen-induced retinopathy in the mouse. Investig. Ophthalmol. Vis. Sci.. 1994 PubMed
173. Takahashi T., Nakamura T., Hayashi A., Kamei M., Nakabayashi M., Okada A.A. et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am. J. Ophthalmol.. 2000 doi:10.1016/S0002-9394(00)00772-8 PubMed
174. Yanagi Y., Tamaki Y., Obata R., Muranaka K., Homma N., Matsuoka H. et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Investig. Ophthalmol. Vis. Sci.. 2002 PubMed
175. Kwak N., Okamoto N., Wood J.M., Campochiaro P.A.. VEGF is major stimulator in model of choroidal neovascularization. Investig. Ophthalmol. Vis. Sci.. 2000 PubMed
176. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA. 1995 doi:10.1073/pnas.92.23.10457 PubMed
177. Zambarakji H.J., Nakazawa T., Connolly E., Lane A.M., Mallemadugula S., Kaplan M. et al. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Investig. Ophthalmol. Vis. Sci.. 2006 doi:10.1167/iovs.05-0855 PubMed
178. Zhao F., Anderson C., Karnes S., Zhou Q., Ma J., Jin Z.G. et al. Expression, regulation and function of miR-126 in the mouse choroid vasculature. Exp. Eye Res.. 2018 doi:10.1016/j.exer.2018.02.026 PubMed
179. Bai X., Luo J., Zhang X., Han J., Wang Z., Miao J. et al. MicroRNA-126 Reduces Blood-Retina Barrier Breakdown via the Regulation of VCAM-1 and BCL2L11 in Ischemic Retinopathy. Ophthalmic Res.. 2017 doi:10.1159/000454716 PubMed
180. Hartmann D., Thum T.. MicroRNAs and vascular (dys)function. Vascul. Pharmacol.. 2011 doi:10.1016/j.vph.2011.07.005 PubMed
181. Westenskow P.D., Kurihara T., Aguilar E., Scheppke E.L., Moreno S.K., Wittgrove C. et al. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. J. Clin. Invest.. 2013 doi:10.1172/JCI70230 PubMed
182. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L. et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat. Med.. 2010 doi:10.1038/nm.2186 PubMed
183. Anand S., Cheresh D.A.. MicroRNA-mediated regulation of the angiogenic switch. Curr. Opin. Hematol.. 2011 doi:10.1097/MOH.0b013e328345a180 PubMed
184. Mulik S., Xu J., Reddy P.B., Rajasagi N.K., Gimenez F., Sharma S. et al. Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. Am. J. Pathol.. 2012 doi:10.1016/j.ajpath.2012.04.014 PubMed
185. Kent O.A., McCall M.N., Cornish T.C., Halushka M.K.. Lessons from miR-143/145: The importance of cell-type localization of miRNAs. Nucleic Acids Res.. 2014 doi:10.1093/nar/gku461 PubMed
186. Dimitrova N., Gocheva V., Bhutkar A., Resnick R., Jong R.M., Miller K.M. et al. Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discov.. 2016 doi:10.1158/2159-8290.CD-15-0854 PubMed
187. Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F. et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev.. 2009 doi:10.1101/gad.1842409 PubMed
188. Hui Y., Yin Y.. MicroRNA-145 attenuates high glucose-induced oxidative stress and inflammation in retinal endothelial cells through regulating TLR4/NF-kappaB signaling. Life Sci.. 2018 doi:10.1016/j.lfs.2018.06.005 PubMed
189. Li X., Zhao F., Xin M., Li G., Luna C., Li G. et al. Regulation of intraocular pressure by microRNA cluster miR-143/145. Sci. Rep.. 2017 doi:10.1038/s41598-017-01003-z PubMed
190. Zhang J., Cui C., Xu H.. Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5. Biosci. Biotechnol. Biochem.. 2019 doi:10.1080/09168451.2019.1630251 PubMed
191. Alexandrov P.N., Dua P., Lukiw W.J.. Up-Regulation of miRNA-146a in Progressive, Age-Related Inflammatory Neurodegenerative Disorders of the Human CNS. Front. Neurol.. 2014 doi:10.3389/fneur.2014.00181 PubMed
192. Kowluru R.A., Koppolu P., Chakrabarti S., Chen S.. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res.. 2003 doi:10.1080/10715760310001604189 PubMed
193. Cowan C., Muraleedharan C.K., O’Donnell J.J., Singh P.K., Lum H., Kumar A. et al. MicroRNA-146 inhibits thrombin-induced NF-kappaB activation and subsequent inflammatory responses in human retinal endothelial cells. Investig. Ophthalmol. Vis. Sci.. 2014 doi:10.1167/iovs.13-13631 PubMed
194. Ye E.A., Steinle J.J.. miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-kappaB and TNFalpha to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose. Mediators Inflamm.. 2016 doi:10.1155/2016/3958453 PubMed
195. Wang Q., Bozack S.N., Yan Y., Boulton M.E., Grant M.B., Busik J.V.. Regulation of retinal inflammation by rhythmic expression of MiR-146a in diabetic retina. Investig. Ophthalmol. Vis. Sci.. 2014 doi:10.1167/iovs.13-13076 PubMed
196. Yan Y., Salazar T.E., Dominguez J.M., Nguyen D.V., Li Calzi S., Bhatwadekar A.D. et al. Dicer expression exhibits a tissue-specific diurnal pattern that is lost during aging and in diabetes. PLoS ONE. 2013 doi:10.1371/journal.pone.0080029 PubMed
197. Chen S., Feng B., Thomas A.A., Chakrabarti S.. miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. PLoS ONE. 2017 doi:10.1371/journal.pone.0173918 PubMed
198. Zhuang P., Muraleedharan C.K., Xu S.. Intraocular Delivery of miR-146 Inhibits Diabetes-Induced Retinal Functional Defects in Diabetic Rat Model. Invest. Ophthalmol. Vis. Sci.. 2017 doi:10.1167/iovs.16-21223 PubMed
199. Bender T.P., Kremer C.S., Kraus M., Buch T., Rajewsky K.. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat. Immunol.. 2004 doi:10.1038/ni1085 PubMed
200. Thomas M.D., Kremer C.S., Ravichandran K.S., Rajewsky K., Bender T.P.. c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity. 2005 doi:10.1016/j.immuni.2005.08.005 PubMed
201. Xiao C., Calado D.P., Galler G., Thai T.H., Patterson H.C., Wang J. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007 doi:10.1016/j.cell.2007.07.021 PubMed
202. Li J., Zhang Y., Liu Y., Dai X., Li W., Cai X. et al. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J. Biol. Chem.. 2013 doi:10.1074/jbc.M113.489302 PubMed
203. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z. et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell. 2010 doi:10.1016/j.molcel.2010.06.010 PubMed
204. Narasaraju T., Shukla D., More S., Huang C., Zhang L., Xiao X. et al. Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury. Am. J. Respir. Cell Mol. Biol.. 2015 doi:10.1165/rcmb.2013-0021OC PubMed
205. Pilakka-Kanthikeel S., Raymond A., Atluri V.S., Sagar V., Saxena S.K., Diaz P. et al. Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a. J. Neuroinflamm.. 2015 doi:10.1186/s12974-015-0285-9 PubMed
206. O’Connell R.M., Kahn D., Gibson W.S., Round J.L., Scholz R.L., Chaudhuri A.A. et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010 doi:10.1016/j.immuni.2010.09.009 PubMed
207. Krichevsky A.M., Gabriely G.. miR-21: A small multi-faceted RNA. J. Cell Mol. Med.. 2009 doi:10.1111/j.1582-4934.2008.00556.x PubMed
208. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008 doi:10.1038/nature07511 PubMed
209. Chen Q., Qiu F., Zhou K., Matlock H.G., Takahashi Y., Rajala R.V.S. et al. Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARalpha. Diabetes. 2017 doi:10.2337/db16-1246 PubMed